[
  {
    "ts": "2026-02-14T06:28:05+00:00",
    "headline": "Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS […]",
    "url": "https://finance.yahoo.com/news/daiwa-downgrades-pfizer-pfe-neutral-062805334.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "2417cbac-1390-3f06-b6f0-b680891fdb3a",
      "content": {
        "id": "2417cbac-1390-3f06-b6f0-b680891fdb3a",
        "contentType": "STORY",
        "title": "Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS […]",
        "pubDate": "2026-02-14T06:28:05Z",
        "displayTime": "2026-02-14T06:28:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ad5ab9008999bda323a107790a6dab9b",
          "originalWidth": 640,
          "originalHeight": 427,
          "caption": "Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CncPfS_Mqj5tx.LtSIbZSQ--~B/aD00Mjc7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ad5ab9008999bda323a107790a6dab9b.cf.webp",
              "width": 640,
              "height": 427,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kTdkjgY5eFmOS7TjNI_NNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ad5ab9008999bda323a107790a6dab9b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/daiwa-downgrades-pfizer-pfe-neutral-062805334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/daiwa-downgrades-pfizer-pfe-neutral-062805334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-14T19:04:19+00:00",
    "headline": "Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25",
    "summary": "Oric Pharmaceuticals (NASDAQ:ORIC) used a fireside chat at the Guggenheim Biotech Conference to outline development priorities for its two lead oncology programs and to reiterate its expected 2025 milestones, including plans to initiate a Phase 3 study in prostate cancer in the first half of the yea",
    "url": "https://www.marketbeat.com/instant-alerts/oric-pharmaceuticals-highlights-2025-milestones-at-guggenheim-targets-phase-3-prostate-trial-in-1h25-2026-02-14/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "3f66efa7-4e5a-3672-8d8f-54da896a09dd",
      "content": {
        "id": "3f66efa7-4e5a-3672-8d8f-54da896a09dd",
        "contentType": "STORY",
        "title": "Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25",
        "description": "",
        "summary": "Oric Pharmaceuticals (NASDAQ:ORIC) used a fireside chat at the Guggenheim Biotech Conference to outline development priorities for its two lead oncology programs and to reiterate its expected 2025 milestones, including plans to initiate a Phase 3 study in prostate cancer in the first half of the yea",
        "pubDate": "2026-02-14T19:04:19Z",
        "displayTime": "2026-02-14T19:04:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/43e98d6854ef675618a8efc0fe7ce597",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Oric Pharmaceuticals logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WZr5dGVY7nXK1LX8b2Xw0g--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/43e98d6854ef675618a8efc0fe7ce597.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XlpPKiAB6MxgbmWd4SlctA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/43e98d6854ef675618a8efc0fe7ce597.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/oric-pharmaceuticals-highlights-2025-milestones-at-guggenheim-targets-phase-3-prostate-trial-in-1h25-2026-02-14/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/oric-pharmaceuticals-highlights-2025-milestones-190419187.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ORIC"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]